Evaluation of a Phone Call Reminder Strategy in the Surveillance of Patients with Gastric Precancerous Lesions Lost to Follow-Up.

Atrophic gastritis Early detection Gastric cancer Gastric precancerous lesions Intestinal metaplasia

Journal

Gastrointestinal tumors
ISSN: 2296-3774
Titre abrégé: Gastrointest Tumors
Pays: Switzerland
ID NLM: 101644585

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 21 01 2020
accepted: 22 05 2020
entrez: 11 11 2020
pubmed: 12 11 2020
medline: 12 11 2020
Statut: ppublish

Résumé

Surveillance of gastric precancerous lesions (GPL) may reduce gastric cancer (GC)-related mortality, but some patients with GPL are lost to follow-up. The aim of this study was to evaluate the feasibility and efficacy of a "phone-call" strategy in surveillance of the lost to follow-up patients. Among all the patients diagnosed with GPL (atrophic gastritis, intestinal metaplasia, low-grade dysplasia) between 2000 and 2015, we identified those who should undergo surveillance endoscopy according to the current guidelines. They were contacted by telephone and invited to undergo endoscopy with gastric biopsies for histological analysis. Among 535 patients with GPL, 134 were contacted. Sixty-two (46%) could not be joined, 36 did not have endoscopy for other reasons, and finally, 36 patients (22 males, median age 65 years) were included. After the median time interval of 57 months between 2 endoscopies, 18 patients showed stability, 11 regression, and 7 progression of GPL, including 1 patient who developed GC. Despite several telephone calls, only one-third of the contacted patients could be brought to surveillance endoscopy. Most of the patients showed stability of GPL, but 1 progressed to GC and could be successfully treated.

Sections du résumé

BACKGROUND BACKGROUND
Surveillance of gastric precancerous lesions (GPL) may reduce gastric cancer (GC)-related mortality, but some patients with GPL are lost to follow-up.
OBJECTIVE OBJECTIVE
The aim of this study was to evaluate the feasibility and efficacy of a "phone-call" strategy in surveillance of the lost to follow-up patients.
PATIENTS AND METHODS METHODS
Among all the patients diagnosed with GPL (atrophic gastritis, intestinal metaplasia, low-grade dysplasia) between 2000 and 2015, we identified those who should undergo surveillance endoscopy according to the current guidelines. They were contacted by telephone and invited to undergo endoscopy with gastric biopsies for histological analysis.
RESULTS RESULTS
Among 535 patients with GPL, 134 were contacted. Sixty-two (46%) could not be joined, 36 did not have endoscopy for other reasons, and finally, 36 patients (22 males, median age 65 years) were included. After the median time interval of 57 months between 2 endoscopies, 18 patients showed stability, 11 regression, and 7 progression of GPL, including 1 patient who developed GC.
CONCLUSION CONCLUSIONS
Despite several telephone calls, only one-third of the contacted patients could be brought to surveillance endoscopy. Most of the patients showed stability of GPL, but 1 progressed to GC and could be successfully treated.

Identifiants

pubmed: 33173774
doi: 10.1159/000508873
pii: gat-0007-0110
pmc: PMC7590752
doi:

Types de publication

Journal Article

Langues

eng

Pagination

110-116

Informations de copyright

Copyright © 2020 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

The authors declare that there is no conflict of interest.

Références

Dig Dis Sci. 2016 Jul;61(7):1870-8
pubmed: 26984230
Dan Med J. 2015 Jun;62(6):
pubmed: 26036882
Community Ment Health J. 2015 Apr;51(3):300-4
pubmed: 25536939
Am J Gastroenterol. 2016 Aug;111(8):1104-13
pubmed: 27185078
Ann Surg Oncol. 2016 Oct;23(11):3677-3683
pubmed: 27216743
Gastrointest Endosc. 2016 Dec;84(6):1010-1017.e1
pubmed: 27327847
BMJ. 2015 Jul 27;351:h3867
pubmed: 26215280
Endoscopy. 2019 Apr;51(4):365-388
pubmed: 30841008
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Gut. 2019 Apr;68(4):585-593
pubmed: 29875257
World J Gastroenterol. 2014 Oct 14;20(38):13842-62
pubmed: 25320521
Health Serv Res. 2012 Apr;47(2):614-32
pubmed: 22091980
Gut. 1999 Nov;45(5):784-90
pubmed: 10517922
Med Care. 2004 Feb;42(2):110-5
pubmed: 14734947
BMJ Open. 2016 Oct 24;6(10):e012116
pubmed: 27798006
Gut. 2017 Jan;66(1):6-30
pubmed: 27707777
Gastroenterology. 2018 Sep;155(3):648-660
pubmed: 29778607
Endoscopy. 2013;45(4):249-56
pubmed: 23533073
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
J Zhejiang Univ Sci B. 2008 Jan;9(1):34-8
pubmed: 18196610
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Endoscopy. 2012 Jan;44(1):74-94
pubmed: 22198778
Cochrane Database Syst Rev. 2013 Dec 05;(12):CD007458
pubmed: 24310741
Gastroenterology. 2008 Apr;134(4):945-52
pubmed: 18395075
Am J Surg Pathol. 1996 Oct;20(10):1161-81
pubmed: 8827022
Psychiatr Serv. 2000 Jul;51(7):885-9
pubmed: 10875952

Auteurs

Nicolas Chapelle (N)

CHU de Nantes, Hôtel Dieu, Institut des Maladies de l'Appareil Digestif, Nantes, France.
Université de Nantes, Nantes, France.
INSERM, U1235, Nantes, France.

Iva Jirka (I)

CHU de Nantes, Hôtel Dieu, Institut des Maladies de l'Appareil Digestif, Nantes, France.

Matthieu Péron (M)

CHU de Nantes, Hôtel Dieu, Institut des Maladies de l'Appareil Digestif, Nantes, France.
Université de Nantes, Nantes, France.

Lucille Quénéhervé (L)

CHU de Nantes, Hôtel Dieu, Institut des Maladies de l'Appareil Digestif, Nantes, France.
Université de Nantes, Nantes, France.
INSERM, U1235, Nantes, France.

Estelle Cauchin (E)

CHU de Nantes, Hôtel Dieu, Institut des Maladies de l'Appareil Digestif, Nantes, France.
INSERM, U1235, Nantes, France.

Yann Touchefeu (Y)

CHU de Nantes, Hôtel Dieu, Institut des Maladies de l'Appareil Digestif, Nantes, France.
INSERM, U1235, Nantes, France.

Emmanuel Coron (E)

CHU de Nantes, Hôtel Dieu, Institut des Maladies de l'Appareil Digestif, Nantes, France.
Université de Nantes, Nantes, France.
INSERM, U1235, Nantes, France.

Jean-François Mosnier (JF)

Université de Nantes, Nantes, France.
Service d'Anatomie Pathologique, CHU de Nantes, Nantes, France.

Tamara Matysiak-Budnik (T)

CHU de Nantes, Hôtel Dieu, Institut des Maladies de l'Appareil Digestif, Nantes, France.
Université de Nantes, Nantes, France.
INSERM, U1235, Nantes, France.

Classifications MeSH